Tech Session I: Nanomedicine and Nanoscale Delivery (Focus: Immuno)
Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy in Multiple Myeloma
Tuesday, July 15, 2025
11:05 AM - 11:16 AM EDT
Location: 120 B/C
Introduction: Bispecific T-cell engagers (BiTE)s have shown promising efficacy, but challenges remain in heterogeneity and cytokine release syndrome (CRS) [1,2]. We present Multi-Antigen T Cell Hybridizers (MATCH), a two-component system comprising a B-cell targeting Fab’ conjugated to a 25-base morpholino oligonucleotide (Fab’B cell antigen-MORF1), and a T-cell engager, anti-CD3 Fab’ with the complementary oligonucleotide (Fab’CD3-MORF2) [3]. This modular system enables pre-targeting to B cells and recruiting T cells by MORF hybridization, offering versatile cancer targeting and reduced toxicity (Fig. 1A).
Learning Objectives:
At the completion of this activity, participants will know
Understand the design and mechanism of MATCH therapy.
Evaluate the efficacy and safety of MATCH in preclinical models.
Explore the translational potential of MATCH therapy.
Jiahui Li – Student, University of utah; Hasan Al Faruque – Pos doc, University of Utah; Douglas Sborov – Associate Professor, University of Utah; Jiyuan Yang – Research Professor, University of Utah; Jindřich Kopeček – Professor, University of Utah
